Higher baseline irisin concentrations are associated with greater reductions in glycemia and insulinemia after weight loss in obese subjects

Nutrition and Diabetes

Volumn 4, Issue 2, 2014, Pages

  Lopez Legarrea, P ^a,b   De La Iglesia, R ^a   Crujeiras, A B ^c,d,e   Pardo, M ^c,d   Casanueva, F F ^d   Zulet, M A ^a,c   Martinez, J A ^a,c  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE CHILE   (Chile)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^e BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; IRISIN;

ADULT; AGED; ARTICLE; CARBOHYDRATE INTAKE; CONTROLLED STUDY; DIABETES MELLITUS; DIET RESTRICTION; DIET THERAPY; FAT MASS; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HORMONE BLOOD LEVEL; HUMAN; INSULINEMIA; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; OBESITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; WEIGHT REDUCTION;

EID: 84898947471     PISSN: None     EISSN: 20444052     Source Type: Journal    
DOI: 10.1038/nutd.2014.7     Document Type: Article

References (24)

1. Straughen JK, Trudeau S, Misra VK. Changes in adipose tissue distribution during pregnancy in overweight and obese compared with normal weight women. Nutr Diabetes 2013; 3: e84.
2. Bostrom P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC et al. A PGC1-alphadependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 2012; 481: 463-468.
3. Stengel A, Hofmann T, Goebel-Stengel M, Elbelt U, Kobelt P, Klapp BF. Circulating levels of irisin in patients with anorexia nervosa and different stages of obesity-Correlation with body mass index. Peptides 2013; 39: 125-130.
4. Liu JJ, Wong MD, Toy WC, Tan CS, Liu S, Ng XW et al. Lower circulating irisin is associated with type 2 diabetes mellitus. J Diabetes Complications 2013; 27: 365-369.
5. Roberts MD, Bayless DS, Company JM, Jenkins NT, Padilla J, Childs TE et al. Elevated skeletal muscle irisin precursor FNDC5 mRNA in obese OLETF rats. Metabolism 2013; 62: 1052-1056.
6. Roca-Rivada A, Castelao C, Senin L, Landrove M, Baltar J, Crujeiras A et al. FNDC5/irisin is not only a myokine but also an adipokine. PLoS One 2013; 8: e60563.
7. Moreno-Navarrete JM, Ortega F, Serrano M, Guerra E, Pardo G, Tinahones F et al. Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. J Clin Endocrinol Metab 2013; 98: E769-E778.
8. Huh JY, Panagiotou G, Mougios V, Brinkoetter M, Vamvini MT, Schneider BE et al. FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism 2012; 61: 1725-1738.
9. Lopez-Legarrea P, de la Iglesia R, Abete I, Bondia-Pons I, Navas-Carretero S, Forga L et al. Short-term role of the dietary total antioxidant capacity in two hypocaloric regimes on obese with metabolic syndrome symptoms: The RESMENA randomized controlled trial. Nutr Metab (Lond) 2013; 10: 22.
10. Lopez-Legarrea P, De la Iglesia R, Abete I, Navas-Carretero S, Martinez JA, Zulet MA. The protein type within a hypocaloric diet affects obesity-related inflammation: The RESMENA project. Nutrition 2013; doi:10.1016/j.nut.2013.09.009.
11. Crujeiras AB, Goyenechea E, Abete I, Lage M, Carreira MC, Martinez JA et al. Weight regain after a diet-induced loss is predicted by higher baseline leptin and lower ghrelin plasma levels. J Clin Endocrinol Metab 2010; 95: 5037-5044.
12. Castillo-Quan JI. From white to brown fat through the PGC-1alpha-dependent myokine irisin: implications for diabetes and obesity. Dis Model Mech 2012; 5: 293-295.
13. Kelly DP. Medicine. Irisin, light my fire. Science 2012; 336: 42-43.
14. Sanchis-Gomar F, Lippi G, Mayero S, Perez-Quilis C, Garcia-Gimenez JL. Irisin: A new potential hormonal target for the treatment of obesity and type 2 diabetes. J Diabetes 2012; 4: 196.
15. Bostrom PA, Fernandez-Real JM. Metabolism: irisin, the metabolic syndrome and follistatin in humans. Nat Rev Endocrinol 2014; 10: 11-12.
16. Katcher HI, Legro RS, Kunselman AR, Gillies PJ, Demers LM, Bagshaw DM et al. The effects of a whole grain-enriched hypocaloric diet on cardiovascular disease risk factors in men and women with metabolic syndrome. Am J Clin Nutr 2008; 87: 79-90.
17. Al-Daghri N, Alkharfy K, Rahman S, Amer O, Vinodson B, Sabico S et al. Irisin as a predictor of glucose metabolism in children: Sexually dimorphic effects. Eur J Clin Invest 2013; e-pub ahead of print 5 November 2013; doi:10.1111/eci.12196.
18. Karpe F, Dickmann JR, Frayn KN. Fatty acids, obesity, and insulin resistance: Time for a reevaluation. Diabetes 2011; 60: 2441-2449.
19. Swick AG, Orena S, O'Connor A. Irisin levels correlate with energy expenditure in a subgroup of humans with energy expenditure greater than predicted by fat free mass. Metabolism 2013; 62: 1070-1073.
20. Zhang HJ, Zhang XF, Ma ZM, Pan LL, Chen Z, Han HW et al. Irisin is inversely associated with intrahepatic triglyceride contents in obese adults. J Hepatol 2013; 59: 557-562.
21. Park KH, Zaichenko L, Brinkoetter M, Thakkar B, Sahin-Efe A, Joung KE et al. Circulating irisin in relation to insulin resistance and the metabolic syndrome. J Clin Endocrinol Metab 2013; 98: 4899-4907.
22. Choi YK, Kim MK, Bae KH, Seo HA, Jeong JY, Lee WK et al. Serum irisin levels in new-onset type 2 diabetes. Diabetes Res Clin Pract 2013; 100: 96-101.
23. Nolan CJ, Damm P, Prentki M. Type 2 diabetes across generations: from pathophysiology to prevention and management. Lancet 2011; 378: 169-181.
24. Makris A, Darcey VL, Rosenbaum DL, Komaroff E, Vander Veur SS, Collins BN et al. Similar effects on cognitive performance during high- And low-carbohydrate obesity treatment. Nutr Diabetes 2013; 3: e89.